vs
Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $110.0M, roughly 1.6× FIRSTSUN CAPITAL BANCORP). FIRSTSUN CAPITAL BANCORP runs the higher net margin — 19.6% vs 1.6%, a 18.0% gap on every dollar of revenue. Over the past eight quarters, FIRSTSUN CAPITAL BANCORP's revenue compounded faster (6.9% CAGR vs -0.2%).
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FSUN vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $110.0M | $177.4M |
| Net Profit | $21.6M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 19.6% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | -8.4% | — |
| EPS (diluted) | $0.76 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.0M | $177.4M | ||
| Q4 25 | $110.2M | $196.9M | ||
| Q3 25 | $107.3M | $179.5M | ||
| Q2 25 | $105.6M | $181.1M | ||
| Q1 25 | $96.2M | $168.9M | ||
| Q4 24 | $98.7M | $187.3M | ||
| Q3 24 | $98.2M | $168.6M | ||
| Q2 24 | $96.2M | $178.0M |
| Q1 26 | $21.6M | $2.9M | ||
| Q4 25 | $24.8M | — | ||
| Q3 25 | $23.2M | $5.4M | ||
| Q2 25 | $26.4M | $-4.8M | ||
| Q1 25 | $23.6M | $4.8M | ||
| Q4 24 | $16.4M | — | ||
| Q3 24 | $22.4M | $-143.5M | ||
| Q2 24 | $24.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 29.0% | 1.2% | ||
| Q3 25 | 26.4% | 3.5% | ||
| Q2 25 | 31.2% | 4.7% | ||
| Q1 25 | 30.9% | 1.2% | ||
| Q4 24 | 20.4% | 13.2% | ||
| Q3 24 | 29.1% | -82.8% | ||
| Q2 24 | 32.3% | 15.9% |
| Q1 26 | 19.6% | 1.6% | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 21.6% | 3.0% | ||
| Q2 25 | 25.0% | -2.7% | ||
| Q1 25 | 24.5% | 2.8% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 22.8% | -85.1% | ||
| Q2 24 | 25.5% | 10.6% |
| Q1 26 | $0.76 | $0.07 | ||
| Q4 25 | $0.89 | $0.05 | ||
| Q3 25 | $0.82 | $0.12 | ||
| Q2 25 | $0.93 | $-0.11 | ||
| Q1 25 | $0.83 | $0.10 | ||
| Q4 24 | $0.57 | $0.38 | ||
| Q3 24 | $0.79 | $-3.11 | ||
| Q2 24 | $0.88 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $413.7M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $653.9M |
| Total Assets | $8.6B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.7M | $144.3M | ||
| Q4 25 | $652.6M | $238.4M | ||
| Q3 25 | $659.9M | $246.3M | ||
| Q2 25 | $785.1M | $445.9M | ||
| Q1 25 | $621.4M | $493.6M | ||
| Q4 24 | $615.9M | $484.6M | ||
| Q3 24 | $573.7M | $453.8M | ||
| Q2 24 | $535.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.2B | $653.9M | ||
| Q4 25 | $1.2B | $693.1M | ||
| Q3 25 | $1.1B | $727.2M | ||
| Q2 25 | $1.1B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.0B | $778.3M | ||
| Q3 24 | $1.0B | $749.6M | ||
| Q2 24 | $996.6M | $879.3M |
| Q1 26 | $8.6B | $1.2B | ||
| Q4 25 | $8.5B | $1.3B | ||
| Q3 25 | $8.5B | $1.3B | ||
| Q2 25 | $8.4B | $1.5B | ||
| Q1 25 | $8.2B | $1.6B | ||
| Q4 24 | $8.1B | $1.6B | ||
| Q3 24 | $8.1B | $1.5B | ||
| Q2 24 | $8.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
